86 Matching Annotations
  1. Aug 2019
  2. Jun 2019
    1. Dominance of regulatory transitional B cellsand lower memory B cells in HBsAgpositive compared to negative newborns
    2. Post vaccination enhanced expression of activation marker CD69 and Chemokine receptor CCR5 on memory B cells in HBV positive newborns
    3. Post-vaccination declination of Transitional B cell population and increase in memory B cells in HBV positive newborns
    4. Increased Chemokine and Toll like receptor on T cells after vaccination in HBV positive newborns.
    5. Vaccination improved the Chemokine receptor CCR1, CCR3, CCR9 and Toll like receptor TLR2, TLR4 and TLR9 expression in HBsAgpositive newborns compared to healthy newborns.
    6. T cell frequencies(Post vaccination response)
    7. Post-vaccination immune responses in newborns
    8. IFN γ production by CD8 T cells upon stimulation with PMA and viral peptides
    9. Decreased CD3 ζ chain expression on CD8 T cells in HBsAgpositive newborns
    10. Phenotypic and Functional Characterization of CD8 T cells in cord blood
    11. Cord Blood immune profiles of HBV positive newborns at birth(Cord blood vs. peripheral blood)
    12. Pre-vaccination:Lower Chemokine and Toll like receptor expression in HBsAgpositive newborns:
    13. T cell phenotypic distribution in HBsAgPositive, HBsAgNegative from HBsAg positive mothers and healthy newborns.
    14. Clinical characteristics of the subjects
    15. CD107a expression (marker of cytotoxicity)
    1. Statistical Analysis
    2. CFSE proliferation assay
    3. CD107a Degranulation Assay
    4. Flow cytometric analysis of cytokine production (IFN-γ)by intracellular staining
    5. Flow cytometric analysis of intracellular CD3ζ chain expression
    6. Cell surface and Intracellular staining and Flow Cytometric Analysis
    7. Freezingor storageof cells
    8. Cell Counting
    9. Separation of Peripheral Blood Mononuclear Cells(PBMCs)from whole blood
    10. Virological assessment: Quantitative RT-PCR detection of HBV DNA
    11. Serological and Virological Assessment
    12. HBV vaccination of the newborn
    13. Sample Collection
    14. Healthy Controls
    1. Statistical analysis
    2. NiSO4. 6H2O stock soloution
    3. Nonidet-P40 (NP40) buffer for Ni-NTA pull down
    4. Low-pH antibody elution buffer
    5. Cytoskeleton extraction buffer (CSE)
    6. Semi dry transfer buffer
    7. GST elution buffer
    8. Ni-NTA elution buffer
    9. Lysis buffer for Ni-NTA and glutathione purification
    10. 1X TBST
    11. 1X TBS
    12. 1X PBS
    13. Composition of buffers and solutions
    14. GST-pull down
    15. Surface plasmon resonance (SPR) measurements
    16. Expression and purification of recombinant proteins
    17. Immunofluorescence studies in SW80 cells for β-catenin under nickel induced condition
    18. Luciferase assay in SW480 cells under nickel induced condition
    19. Ni-NTA pull down
    20. Stripping of Ni-NTA agarose beads
    21. Nuclear and cytoplasmic fractionation
    22. Large scale purification of BPN in CHO cells from pSecTag2 vector
    23. Luciferase reporter assay
    24. Immunoprecipitation and western Blotting
    25. Immunofluorescence
    26. Generation of polyclonal antibodies against GFP, APC and β-catenin
    27. RNA Interference
    28. Cell transfection
    29. Secondary antibodies
    30. Primary antibodies
    31. Antibodies used in our study
    32. Cell culture
    33. General reagents and plastic wares
    34. Medium and Serum
    35. Animals
    36. pGEX6P2-BPN (1-993 a.a)
    37. pET30a-GFP-FL (GFP antigen)
    38. pET30-b-APC Nde/Sca (1211-1495 a.a) (antigen for APC antibody)
    39. pET30a-β-catenin-FL (Antigen for -catenin antibody)
    40. GFP-β-cateninC-C (423-634 a.a) (ARM-C)
    41. GFP-β-catenin-C-N (151-423 a.a) (ARM-N)
    42. GFP-β-catenin-C (ARM)
    43. GFP-β-catenin- C (634 -781 a.a)
    44. GFP-β-catenin- a.a
    45. GFP-β-catenin T41A mutant
    46. Constructs made in the study
    47. GFP-β-catenin-FL